Retinoic acid activity on mamalian embryo in organ culture and evaluation of hazard and risk in correlation studies between molecular descriptors and ADMET parameters in a series of X-category drugs

Abstr. no. Abstr. code

815 **PC-006**

Jadrijević-Mladar Takač M.¹, Crnek Kunstelj V.², Barbarić M.¹ and Takač V.³

¹Faculty of Pharmacy and Biochemistry, Department of Medicinal Chemistry, University of Zagreb, Croatia ²School of Medicine, Department of Biology, University of Zagreb, Croatia ³Health Pharmacy Institution Štefanić, Zagreb, Croatia

INTRODUCTION

The active derivative of vitamin A, retinoic acid (RA), as essential component of cell-cell signaling during vertebrate organogenesis is important for normal embryonic development. RA is an endogenous agonist for retinoic acid receptors (RARs), the type II of nuclear receptors (RARa, RARß and RARy) which are ligandcontrolled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth, differentiation, survival and death. The concentration of RA must be within a very narrow range in order to avoid both deficiency and toxicity because the adding of vitamin A or RA to embryos can easily induce teratogenic effects including major alterations in organogenesis. (1-3) The results of many previous studies indicate that all endogenous retinoids (retinol, retinal, RA) are toxic and in some cases teratogenic (4, 5), therefore they are listed in the FDA Pregnancy category X-drugs among a very diverse group of drugs with different structural features, mechanisms of action and clinical indications. (6) The influence of RA on development of embryonic teratoma was also a subject of our previous in vitro investigations (7, 8). In addition, in this study we explored molecular features of selected pregnancy category X drugs, including retinol, retinal and retinoic acid, by correlation studies between computed molecular descriptors (MDs), predicted drug-likeness scores (dls) and ADMET properties.

METHODS

Meta


gird


Embryos in

developed in

teratomas


cultures









cut at the level o the amnion





8. Methotrexate


11. Mestranol, R = OH, R¹ = CCH, R²= CH, 12. Estrone sulfate, RR¹ = O, R² = SO₃H











Differentiated tissues	serum suplemented medium (MEM/RS) ed tissues 14 days 5 – 14 days of drugs exposu										
-	Control	RA (10 ⁻⁵ M)	NGF (100 ng/mL)	RA /NG							
Treatmen and number (%) of explants	32	30	28	15							
Keratinized epidermis	29 (90.0)	28 (93.0)	26 (93)	0 (0.0							
Imature epidermis	3 (9.0)	2 (6.0)	2 (7.0)	15 (100							
Neural tissue	20 (62.0)	20 (66.0)	14 (50.0)	15 (100							
Gut epithelium	25 (78.0)	29 (96.0)	18 (64.0)	14 (93.							
Gland epithelium	7 (21.0)	3 (10.0)	6 (21.0)	0 (0.0							
Cartilage	24 (75.0)	1 (3.0)	19 (68.0)	0 (0.0							
Myotubes	6 (18.0)	8 (26.0)	9 (32.0)	7 (46.0							
Smuth muscles	5 (15.0)	7 (23.0)	7 (25.0)	7 (46.0							

Table 1. The results of teratoma developments investigation







Table 3. The number (%) of drugs with computed drug-likeness scores (dls) per each category

Drug-likeness	GPCR dls	ICM dls	KI dls	NRL dls	PI dls	EI dls									
scores (dls)	Number of drugs (%)														
0.50 - 1.70	3 (8.0)	1 (2.7)	0 (0.0)	17 (45.9)	2 (5.0)	17 (45.9)									
0.20 - 0.49	16 (43.2)	9 (24.3)	2 (5.0)	7 (18.9)	4 (10.8)	9 (24.3)									
≤ 0.19	18 (48.7)	27 (72.9)	35 (94.6)	13 (35.1)	31 (83.8)	11 (29.8)									





Tissue differentiation in teratoma developed from cultivated rat embryo: a – lentoid. b – neural tissue. c – gut epithelium. d - cartilage



Culture medium was put under the gird to keep the lens paper wet. Cultivated media: MEM (Control) = Eagle's minimal esential medium + rat serum (50%); Treatment applied: 10⁻⁵ M RA. 100 ng/mL NGF or combination from 5th to 14th days of culture.


Fig. 1. Schematic display of teratoma development

B) Correlation studies

Drugs (n = 37) in a series of pregnancy category X-drugs. labelled by FDA as contraindicated in pregnancy. were used in this study. Computed MDs and ADMET parameters of toxicity of investgated molecules were predicted by ADMET Predictor Module[™] 6.5 (Simulations Plus. Inc. USA). Drug-likeness scores were computed by Molinspiration Bioactivity Score (v2011.06) (wwwmolinspiration.com). Molecular refractivity and molecular polarizability, as well as Hickel analysis (pl energy) were computed by ChemAxon software (www.chemicalize.org). All correlation analyses were performed using OriginPro 8.0 software (Origin Laboratories. USA).

RESULTS AND CONCLUSIONS

 Mammalian embryo-derived teratomas investigation in organ culture (Fig. 1) treated with with either retinoic acid (RA, $c = 10^{-5}$ mol/L) or neural growth factor (NGF, 100 ng/mL) showed no influence on neural tissue differentiation.



• The combination of RA ($c = 10^{-5}$ mol/L) and NGF (100 ng/mL) influenced the neural tissue differentiation (100%) and the total inhibition of epidermis, gland epithelium and cartilage. (Table 1) • The same effects were observed in experiments of teratoma development treated with RA alone in concentration, $c = 10^{-4}$ mol/L. • The results in this in vitro model revealed the potential teratogenicity of RA in higher concentrations (c = 10⁻⁴ mol/L) or in combination with NGF.

 Computed MDs and ADMET parameters are listed in Table 2. • Drug-likeness scores (dls) analysis revealed that 73 % of investigated molecules are with positive NRL dls and El dls. Out of total, 45.9% of molecules were with 0.5 - 1.7 NRL dls and El dls, while with scores 0.2 – 0.49 were 19% of NRL dls and 24% of El dls (Table 3, Fig. 2). GPCR | dls with dls > 0.5 (8%) and dls between 0.2 and 049 (44%) were also computed.

• Linear correlations were obtained between M_r and V (Fig. 3), also between molecular polarizability and molecular refractivity (Fig. 4). Insignificant collinearities were obtained with NRL dls v.s. MLogP and pl energy. However NRL dls found to increase with increasing of MLogP and decreasing of pI (Fig. 5 and Fig. 6, respectively). In correlations of MLog P and TPSA with TOX hERG, a two sets of molecules were observed, a small subgroup with high collinear relationship between TOX hERG either with MLogP (Fig. 7) or TPSA (Fig. 8), while the other set represents a cluster of diverse molecules including retinoids. It was also found the exponential decrease of TOX

		10	Ethynyl estradiol	4.004	3.679	40.46	296.412	329	0	3	1	2 0	0	4.336	1369.945	189.637	894.289	0.33	0.17	-0.24	1.18	0.03	0.61	33.90	87.374	
		11	Mestranol	4.227	4.101	29.46	310.439	350	1	5	2	2 1	0	4.428	1096.787	26.347	253.23	0.24	0.05	-0.30	1.01	0.00	0.49	33.90	87.374	hERG with the NRL dls decreasing (Fig. 9).
		12	Estron sulfate	2.975	1.534	80.67	350.436	350	0	3	0	1 1	0	4.468	872.248	100.863	1057.492	0.42	0.17	-0.44	0.62	0.62	0.96	35.49	89.074	• For all retinoids $(1 - 5)$ included in this study the predicted ADMET
is is<		13	Methyltestosteron	3.923	3.624	37.3	302.46	350	0	3	0	1 2	0	4.431	1549.547	13.374	604.365	-0.03	-0.14	-0.86	1.17	-0.13	0.57	35.10	89.068	
V2 decomposite 15 Megenitation 4.337 9.38 9.7 9.38 9.2 0 1 1 0 4.66 7.27 9.38 9.20 1.38 0.0 1.38 9.20 1.30 9.21 1.30 0.21 1.30 0.21 1.30 0.21 1.30 0.21 1.30 0.21 1.30 0.21 1.30 0.21		14	Fluoxymestrone	3.2	2.557	57.53	336.45	360.5	0	3	0	1 2	0	3.96	733.015	2.047	620.704	0.04	-0.11	-0.85	1.71	0.55	0.72	35.43	90.189	Risk was 4, CYP Risk 0 and TOX Risk 2, while TOX MUT Risk 1 were
	32. Methysergide	15	Medroxyprogesterone		A CONTRACTOR OF A				0	2	0	0 2	0	4.506									0.54			predicted for retinol (3) and etretinate (4) (Table 2, Fig. 10).
 iii Minimize iiii Minimize iii Minimize iii	Ŷ	16					312.455	357	0	2	0	1 1	0	4.636	728.799	9.323						-0.04	0.67			
i bit i bit <t< td=""><td>он 人</td><td>17</td><td></td><td></td><td></td><td></td><td>298.428</td><td>336</td><td>0</td><td>2</td><td>0</td><td>1 1</td><td>0</td><td>4.458</td><td>807.728</td><td>7.31</td><td></td><td></td><td></td><td></td><td>and the second sec</td><td>-0.09</td><td>0.71</td><td></td><td></td><td>Pregnancy category X drugs have a potential not only for</td></t<>	он 人	17					298.428	336	0	2	0	1 1	0	4.458	807.728	7.31					and the second sec	-0.09	0.71			Pregnancy category X drugs have a potential not only for
$\frac{1}{2}$ $\frac{1}$						-		490	1	6	2	2 2	0	5.265									0.25			teratogenicity but also for other ADRs, therefore their prescription
3. Numerice 1 Iadardene 3. 49 6. 49		19							1	8	2		3	4.416					0100				0.62			
i i< i i< i<	33 Warfarin	20			1	77.76	392.583	455	0	2	1		0	4.361	2133.29		553.347	Articlement	0.33	-0.39			0.68	Contract in a local state		and the use in treatment of patients should be with extreme caution.
i bin i bin <th< td=""><td>SS. Wanann</td><td>21</td><td></td><td></td><td></td><td>70</td><td>4/3.594</td><td>483</td><td>0</td><td>6</td><td>2</td><td>1 2</td><td>4</td><td>6.007</td><td>907.258</td><td></td><td>75.848</td><td></td><td>-0.14</td><td>-0.19</td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	SS. Wanann	21				70	4/3.594	483	0	6	2	1 2	4	6.007	907.258		75.848		-0.14	-0.19						
i bit distribution i d	Γ _ρ	22				12.47	405.971	465.5	1	9	1	2 4	1	7.196						-0.20						
i bit i bit <th< td=""><td>N' N</td><td>23</td><td></td><td></td><td></td><td>40.46</td><td>200.342</td><td>308</td><td>0</td><td>2</td><td>1</td><td></td><td>1</td><td>5.108</td><td></td><td></td><td></td><td>and the second second</td><td>and the second second</td><td>-0.09</td><td>a sectore</td><td>1000 C</td><td>0.13</td><td></td><td></td><td>References</td></th<>	N' N	23				40.46	200.342	308	0	2	1		1	5.108				and the second second	and the second second	-0.09	a sectore	1000 C	0.13			References
indication indicat					and a second sec			315	1	7	1		0	5.424	1695.334	208.131				0.05		-0.07	0.24			
V Parestatin 3.19 5.30 8.8.8 42.0.9 5.40 6.4 3 0 1 0 5.65 10.96 11.55 75.70 0.28 0.4 4.7.9 12.268 Parestatin 2.476 3.592 8.28 411.47 437.5 0 1 0 0.50 32.04 73.03 23.25 15.165 0.41 0.43 0.41 0.43 0.41 0.43 0.41 0.43 0.41 0.41 0.43 0.41 0.43 0.41 <								497	1	2	2		0	4.802	2090 162	50.200				-0.34		-0.08	0.56			
and provide pro	\square \mathbb{R}^2					107111 A045444	402.576	470 E04	0	5	2		0	4.954 E 065	1006.066	141 952	795 705	0.23		-0.33		Landon Contra				2. Duester, G., 2008, Retinoic acid synthesis and signaling during early organogenesis. Cell 134, 921-931.
Jamese (F)		2/					420.595	304 427 E	0	4	3		0	5.005	220 844	70 221	165.705	0.28		-0.32						
No. No. <td></td> <td>20</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td>1</td> <td>2</td> <td>1 2</td> <td>0</td> <td>5.007</td> <td>320.844</td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		20							1	1	2	1 2	0	5.007	320.844					-						
Main Main <th< td=""><td></td><td>29</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>0</td><td>2</td><td></td><td>2</td><td></td><td></td><td></td><td></td><td></td><td>and the second</td><td></td><td>A CONTRACTOR OF</td><td></td><td>and a second second</td><td></td><td></td><td></td></th<>		29							1	0	2		2						and the second		A CONTRACTOR OF		and a second second			
32 Methysegide 1.904 2.939 57.5 367.49 406 0 3 0 1 2 3 3.03 2.638 9.09 0.05 0.07 0.20 0.11 33 Warfarin 2.767 3.034 54.37 306.364 2.99 0 3 0 1 1 0 5.08 0.90 0.01 0.90 0.91		30							0	4	2	0 2	3				F									
A A	Ň								0	2	0	1 2	1									CONTRACTOR 1				
35 36.34 36									0	5	0	1 2	3	5.500									0.28			
And All		55							U	3	0	1 1	0	5.084									-0.10			
36. Triazolam 4.16 3.074 43.07 343.217 322 1 5. 2 1 2 0 5.414 1776.856 17.612 5.256 0.73 0.65 -0.34 -0.51 -0.38 -0.51 -0.38 103.684	c	34	•						0	4	0	2 2	2													mammalian embryo <i>in vitro</i> . Period. Biol. 104, 55-66.
36 Triazolam 4.16 3.074 43.07 343.217 322 1 5 2 1 2 0 5.414 1776.856 17.612 5.256 0.73 0.65 -0.34 -0.51 -0.38 -0.19 35.28 103.684 can be mediated by retinoic acid and dibutyryl-cAMP. Libri. Oncol. 29, 133-141.	36. Triazolam	35							0	1	0	1 0	1								_					8. Crnek-Kunstelj, V., Stipić, J., Stipić-Marković, A., 2001, Differentiation in embryo-derived teratomas in vitro
37 Thalidomide 0.735 0.172 83.55 258.235 231 0 3 4.661 715.799 7.644 527.637 -0.28 -0.13 -0.12 24.01 64.325		36				0.000.000			1	5														There are an included		can be mediated by retinoic acid and dibutyryl-cAMP. Libri. Oncol. 29, 133-141.
		37	Thalidomide	0.735	0.172	83.55	258.235	231	0	3	0	0 3	3	4.661	715.799	7.644	527.637	-0.28	-0.56	-0.70	-0.88	-0.13	-0.12	24.01	64.325	

MLogP - lipophiliciy, TPSA - topological polar surface area, Mr - relative molecular mass, V - volume, Rule of 5 - absorption filter designed by Chris Lipinski et. al., ADMET Risk - a global ris k score, S+Absn Risk - low absorption risk, CYP Risk - MET Risk with inclusion of the CYP substrate rules, TOX Risk - risk of overall toxicity, including mutagenicity, TOX MUT Risk - risk of mutagenicity in S. typhimurium, TOX hERG - inhibition of the hERG potassium channel in human expressed as pIC50 in mol/L), TOX RAT - acute lethal toxicity in rat, TOX BRM Rat, - TD50 value of a particular compound in units of mg/kg/day, TD 50 - dose of a au bstance administered orally to rats over the course of their lifetimes that results in the appearance of tumors in 50 percent of their population), TOX BRM Mouse - TD50 value in mice mg/kg/day, dls - drug-likeness score, GPCR I = G protein-coupled receptor I igand; ICM = ion channel modulator; KI = kinase inhibitor; NRL = nuclear receptor ligand; PI = protease inhibitor; EI = enzyme inhibitor.

ACKNOWLEDGEMENTS - The authors acknowledge to the Ministry of Science, Education and Sports of the Repubic of Croatia, Grant no. 006-0982929-2940 and for the financial support of the University of Zagreb.

Contact e-mail: jmtmilena@gmail.com



37. Thalidomide

34. Fluraze 35. Temaze

Drug Design and Discovery

Milena Jadrijevic-Mladar Takac

MELBOURNE Poster PSWC 2014 presented at:



